Alodia 25 Tablet 30 pcs
৳ 660
Order By Call:
+88 01336 242 802 (Mobile)
+88 01336 242 802 (WhatsApp)
Aglip is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type-2 diabetes mellitus.
Payment Methods
About the Product
Full Description
The recommended dose in patients with normal renal function or mild renal impairment is 25 mg once daily or as directed by the physicians.
Common side effects are nasopharyngitis, headache and upper respiratory tract infection
Aglip is a DPP-4 inhibitor that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing
fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus. Increased
concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are
released into the bloodstream from the small intestine in response to meals. These hormones cause insulin release from the pancreatic beta cells in
a glucose-dependent manner but are inactivated by the DPP-4 enzyme within minutes. GLP-1 also lowers glucagon secretion from pancreatic
alpha cells, reducing hepatic glucose production. In patients with type 2 diabetes, concentrations of GLP-1 are reduced but the insulin response to
GLP-1 is preserved.
